Trastuzumab: a picky partner?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19825955.
- Also identified by DOI 10.1158/1078-0432.CCR-09-1917.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Preclinical and clinical models of HER2-positive breast cancer show that human epidermal growth factor receptor 2 (HER2)-targeted therapy with trastuzumab adds significant benefits and modest risks to conventional cytotoxic therapies. Building on this advance will likely depend on elucidation of relevant signaling pathways and mechanisms of action for effective HER2-targeted therapies.
Medical subject headings
- Antibodies, Monoclonal
- Breast Neoplasms